Transient T cell therapies.
Chimeric antigen receptor (CAR) T cell therapy has achieved clinical success in hematological malignancies, but its reliance on viral vectors and complex ex vivo manufacturing poses challenges related to safety, cost, and scalability. Afterwards, we summarize the ongoing clinical trials of transient CAR-T cell therapy for oncology and non-oncology indications.
Chimeric antigen receptor (CAR) T cell therapy has achieved clinical success in hematological malignancies, but its reliance on viral vectors and complex ex vivo manufacturing poses challenges related to safety, cost, and scalability. Afterwards, we summarize the ongoing clinical trials of transient CAR-T cell therapy for oncology and non-oncology indications.
What the study was
- Study design
- Not specified
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Advances in pharmacology (San Diego, Calif.)
Why it surfaced
Low-signal Novel therapeutics: immunotherapy, CAR-T, targeted therapy entry (Not specified design); retained for topic coverage completeness.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.